Cagrilintide + Semaglutide Blend Research Guide

Overview

Cagrilintide + Semaglutide Blend combines two advanced metabolic compounds for dual-pathway weight management research. This formulation mirrors the investigational CagriSema combination.

Blend Components

Cagrilintide (Amylin Analogue)

• Long-acting amylin receptor agonist
• Reduces appetite and food intake
• Slows gastric emptying
• Regulates postprandial glucose
• Complements GLP-1 mechanism

Semaglutide (GLP-1 Agonist)

• Potent GLP-1 receptor agonist
• Enhances glucose-dependent insulin secretion
• Suppresses appetite via CNS pathways
• Promotes sustained satiety
• Well-characterized metabolic effects

Synergy Mechanism

The combination of amylin and GLP-1 pathways provides complementary appetite suppression through different neurological mechanisms, potentially exceeding single-agent efficacy.

Quality Standards

• Purity: >98% verified by HPLC for each component
• Form: Lyophilized powder
• Storage: -20°C long-term
• Documentation: Full CoA with individual component verification

For research purposes only. Not for human consumption.